Follows adults with myasthenia gravis over time to record symptoms and treatment
Observes people with myasthenia gravis, recording their symptoms, treatment and quality of life.
Plain-language title generated from the registry record
Registry title: Vitaccess Real MG Registry
Key facts
- Where
- Charleston, Houston, Lexington, Lumberton, O'Fallon, and Orange, United StatesSee the 6 sites
Where in United States
- Medical University South CarolinaCharleston, United StatesTaking people
- University of Texas Health Science Center at HoustonHouston, United StatesTaking people
- UK HealthCare - University of KentuckyLexington, United StatesTaking people
- Neurology Associates of South JerseyLumberton, United StatesTaking people
- HSHS St. Elizabeth's HospitalO'Fallon, United StatesTaking people
- UCI HealthOrange, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vitaccess Ltd
- Trial code
- NCT06064461
- Record updated
- 29 July 2025
- Original description
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records.Read full original descriptionShow less
Vitaccess Real MG Registry: A Prospective International Observational Patient Registry in Myasthenia Gravis Linking Clinical and Patient-reported Data.
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records.
Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.
Inclusion: Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG); Resident in one of the scope countries; Access to a smartphone/tablet/computer/laptop; Willing and able to provide informed consent in their local language to take part in the study.
Exclusion: Participation in a clinical trial at the time of study enrolment.